

1 **Efficacy of newly invented temperature and humidity control machine on house dust**  
2 **mite allergen and clinical symptom of dust mite sensitized allergic rhinitis children: a**  
3 **pilot study**

4 Wiparat Manuyakorn, SavitreePadungpak, OrawinLuecha,WasuKamchaisatian,  
5 CherapatSasisakulporn, SoamaratVilaiyuk. VeerapolMonyakul, SuwatBenjaponpitak

6

7 **Correspondence address:**

8 SuwatBenjaponpitak, MD.

9 Associate professor

10 Division of Allergy/Immunology/Rheumatology, Department of Pediatrics,

11 Faculty of Medicine Ramathibodi Hospital, Mahidol University

12 270 Rama 6 Road, Rajthevee District, Bangkok 10400, Thailand

13 Tel: +662-201-1494 Fax: +662-201-1760

14 Email: [suwat.ben@mahidol.ac.th](mailto:suwat.ben@mahidol.ac.th)

15 **Short running title:**

16

17

18

19

20

21

22 **Abstract**

23 **Background:**

24 House dust mite avoidance is advised in dust mite sensitized patients to decrease their risk  
25 of developing symptoms. Maintaining a relative humidity (RH) of less 50% is recommended  
26 for reducing the growth of dust mite.

27 **Objective:**

28 This study was to investigate the efficacy of temperature and humidity control machine on  
29 the level of dust mite allergens and total nasal symptom score (TNSS) in dust mite  
30 sensitized allergic rhinitis children.

31 **Method:**

32 Children (8-15 years) with dust mite sensitized persistentAR were enrolled. The temperature  
33 and humidity control machine was installed in the bedroom for 6 months. TNSSwas  
34 accessed before and every month after machine installingand the level of dust mite allergen  
35 (Der p1 and Der f1) from the mattress were measured before and every 2 months after  
36 machine installingusing enzyme-linked immunosorbent assay (ELISA).

37 **Results:**

38 A total of 7 children were enrolled. The reduction of Der f1 was demonstrated as early as 2  
39 months after installing the machine but the significant difference was seen at 4 months and it  
40 was sustained low throughout 6 months ( $p<0.05$ ). There was a modest but  
41 significantreduction in TNSS at 2 and 4 months ( $p=0.003$ ). Seventy percent of the patients  
42 were able to stop using their intranasal corticosteroids. However, there was no correlation  
43 between TNSS and the level of dust mite antigen.

44 **Conclusions:**

45 The level of house dust mite in the mattress decreases after using temperature and humidity  
46 control machine. This machine mayhave a role in controlling clinical symptom of dust mite  
47 sensitized AR children.

48 Key words: Allergic rhinitis, Dust mite, Der p1, Der f1, children, relative humidity

49

50

51 **Introduction**

52 Allergic rhinitis is a common allergic disease worldwide. It has been proven that more than  
53 600 million patients suffering worldwide. In Thailand, the prevalence of allergic rhinitis  
54 increased from 37.9% in the year 1995 to 50.6% in the year 2001.<sup>1</sup>

55 Clinical symptoms of allergic rhinitis consist of nasal itching, sneezing, watery nasal  
56 discharge, rhinorrhea, and blocked nose. Allergic rhinitis can be classified as intermittent or  
57 persistent and the severity from mild to severe. Medication treatments include antihistamine,  
58 oral leukotriene receptor antagonists, and topical nasal steroid depending on disease  
59 severity.<sup>2</sup> However, allergen avoidance is advocated as a central role for the managements  
60 of allergic rhinitis.<sup>3</sup> House dust mite is the most common aeroallergen sensitization in patients  
61 with respiratory allergy in tropical climate country such as Thailand and Singapore.<sup>4,5</sup> A  
62 recent practice parameter has advised dust mite sensitized patients with asthma or rhinitis to  
63 minimize exposure to dust mite allergens to decrease their risk of developing of symptoms.  
64 Water balance is critical for house dust mite survival. The optimum relative humidity (RH)  
65 more than 65% is needed to maintain their water balance and growth. If humidity decreases  
66 below 50%, mite proliferation decreases and survival is decreased. The temperature also  
67 has an impact on RH, as a result maintaining stable temperature is required to maintain a  
68 stable RH<sup>6</sup>. The present study was to investigate the effect of newly invented temperature  
69 and humidity control machine on the level of dust mite allergen and clinical symptom of dust  
70 mite sensitized allergic rhinitis children. This machine was invented by Dr.  
71 Veerapon Monyakul, King Mongkut's University of Technology Thonburi. This machine has  
72 been shown to provide a precise temperature and desired humidity in the room.<sup>7</sup>

73

74

75

76 **Patients and Methods**


77

78 **Patients**

79 Children aged 8-15 year with persistent allergic rhinitis according to ARIA guideline who  
80 have skin prick test positive to house dust mites (*Dermatophagoides pteronyssinus*  
81 and/or *Dermatophagoides farina*) and had symptom of allergic rhinitis related to the exposure  
82 to house dust mite were eligible for the study. Positive skin test was defined as a wheal  
83 diameter at least 5 mm larger than the control. Patients with multiple sensitization and  
84 previously or current on specific immunotherapy were excluded. Since the temperature and  
85 humidity control machine operate with air-conditioning and the machine was installed in the  
86 bedroom, the enrolled patients' must have air-conditioning in the bedroom.

87 **Study protocol**

88 This study is a 6 month experimental study with 1 month run in period. During running,  
89 intranasal corticosteroids were not allowed, but the patients were allowed to use  
90 decongestant and antihistamine and nasal irrigation. At V0, the patients were evaluated for  
91 total nasal symptom scores (TNSS) and dust mite collection from the mattress in the  
92 bedroom for dust mite antigen measurement. Then, clinical visit and TNSS was assessed  
93 every month after machine installation in the bedroom. The dust mite antigens (Der p1 and  
94 Der f1) were measured every 2 months (Figure 1). TNSS was defined as the sum of the  
95 average score in the past 4 weeks for the 4 individual patients-reported nasal symptoms of  
96 congestion, itching, rhinorrhea, and sneezing (0-3 from mild to severe). After enrollment,  
97 patients were treated their rhinitis according to ARIA guideline<sup>3</sup> and received standard  
98 recommendation for dust mite control. The study was reviewed and approved by the human  
99 rights and ethic committee of Faculty of medicine, Ramathibodi Hospital, Mahidol  
100 University. All enrolled patients and guardian were explained and consented for the study.




112 Figure 1: Study protocol

113 **The temperature and humidity control machine**

114 The temperature and humidity control machine invented by Dr. VeeraponMonyakul, King  
 115 Mongkut's University of Technology Thonburi, Bangkok, Thailand.<sup>7</sup>The temperature and  
 116 humidity control machine consists of a unit of humidifier and a unit of dehumidifier withinthe  
 117 same case. The device has the dimension of 0.3 x 1.0 x 1.2 meters (Width x Length x  
 118 Height)and is similar to a 10,000 BTU air condition (type TURBO A.P.S., Saijo Denki  
 119 International Co., MuangNonthaburi, Thailand).This device does operate with air-  
 120 conditioningunder the automatic control by microprocessor in order to keep the relative  
 121 humidity andtemperature constant at all times, 55% RH and 25 degrees Celsius. The device  
 122 is installed and running incorporated with air-conditioning under the automatic control by  
 123 microprocessor (Figure 2).Therefore, the temperature and humidity in testing room was

124 controlled to be as 25°C and 55% RH. This device has never been used as a commercial  
125 product.



126

Fig (b)

127 **Figure 2: The newly invented temperature and humidity control machine (A). Diagram**  
128 **demonstrating the operation system of the machine with the air condition(B).**

### 129 Mite Allergen Measurement

130 Levels of Der p 1, the major allergen of *Dermatophagoides pteronyssinus* mites and Der f1,  
131 the major allergen of *Dermatophagoides* were measured using the commercial sandwiched  
132 ELISA reagents (Indoor Biotechnology, U.K.) at Siriraj Dust Mite Center for Services and  
133 Research Department of Parasitology, Faculty of Medicine Siriraj Hospital Mahidol  
134 University, Bangkok, Thailand. The lower detection limit is 0.2 microgram of Der f1 and Der  
135 p1 per gram dust.

### 136 Statistical analysis

137 Descriptive analysis was used to report the mean value and standard deviation (sd) of the  
138 data. Comparative analysis between pre and post machine installation was analyzed using  
139 paired Student's t test or ANOVA repeated tests. Correlation between TNSS and the level of  
140 dust mite antigen was analyzed using Pearson correlation. The differences with a p value

141 less than 0.05 were considered statistically significant. Data were analyzed using SigmaPlot  
 142 12.

143

144 **Results**

145 A total of 7 children with house dust mite sensitized allergic rhinitis were enrolled. Four  
 146 children were male, mean age was 9.8 years, mean age of onset was 4 years and mean  
 147 duration of symptom was 4 years. Three children also had asthma. Baseline characteristic of  
 148 the patients was shown in table 1.

149 Table 1: Baseline characteristic of participating children

	<b>Age (yr)</b>	<b>Sex</b>	<b>Duration of AR (yr)</b>	<b>Age of onset (yr)</b>	<b>Other allergic diseases</b>	<b>Severity of AR</b>	<b>Wheal size for DpbySPT</b>	<b>Wheal size for Df By SPT</b>	<b>Baseline TNSS</b>
<b>1</b>	12	M	1	7	Drug allergy	Mild persistent	6*5	8*6 with pseudopod	3.45
<b>2</b>	12	F	7	4	AD,food allergy	Mild persistent	9*7	12*6 with pseudopod	1
<b>3</b>	8	M	2	6	No	Moderate persistent	10*5 with pseudopod	10*5 with pseudopod	6
<b>4</b>	8	M	6	2	Asthma	Mild persistent	7*7	10*6	1
<b>5</b>	11	F	4	7	Asthma	Moderate persistent	10*6	16*15	7.6
<b>6</b>	10	M	1	8	No	Mild persistent	10*25	10*8	3
<b>7</b>	8	F	7	1	Asthma	Mild persistent	17*15	23*13	1.83

150 AR : Allergic Rhinitis, SPT : Skin Prick Test, TNSS: Total Nasal Symptom Scores

151

152

### 153 **Total nasal symptom score after installing the machine**

154 Total nasal symptom score was significantly decreased after 2 months of installation the  
155 machine. However due to the variation in the total nasal symptom score and the small  
156 sample size, the statistically significant difference was seen only at 2 months and 4 months  
157 after installation (Figure 1). Five out of seven patients were able to stop using their intranasal  
158 corticosteroids.

### 159 **The level of Der p1 and Der f1 after installation**

160 There was are a reduction of the level of Der f1 as early as 2 months after installing the  
161 machine but the significant difference was demonstrated at 4 months and it was sustained  
162 low throughout 6 months ( $p < 0.05$ ) (Figure 2). However, the level of Der p1 in the mattress  
163 was lower than 0.2 ug/g dust in 6/7 houses resulting in the non-significant changes in the  
164 level of Der p1 (Figure 3).

165


### 166 **The level of dust mite antigen and TNSS**

167 There was no correlation between the TTNS and the level of Der f1 or Der p1 ( Figure 4  
168 ).Comparison between patient s who had baseline TNSS more than 3 and less than 3, there  
169 was no significant difference between the baseline level of Der f1 level (1.4 vs 2.5 ug/ gram  
170 dust,  $p = 0.4$ )

171

172






173


174 Figure 1 Clinical symptom score in each visit after machine installation. V0=before machine  
 175 installation, V1,2,3,4,5, and 6 represent 1,2,3,4,5 and 6 months after installation respectively.

176 Same symbol represents data from same subject.

177




178




179

180 Figure 2 The level of house dust mite antigen Der f1 (A) and Der p1 (B) in each visit after  
 181 machine installation. V0=before machine installation, V2,4,6 represent 2,4 and 6 months  
 182 after installation respectively. Same symbol represents data from same subject.



183



184

185 Figure 3: The level of house dust mite antigen Der f1 (A) and Der p1 (B) and total nasal  
 186 symptom scores.

187 **Discussion**

188 House dust mite is the major allergen causing symptoms in respiratory allergy especially in  
189 tropical countries especially Thailand.<sup>5</sup>More than 70% of children with respiratory allergy  
190 were sensitized to house dust mites.<sup>8</sup>Current guidelines for allergic rhinitis and asthma  
191 management have emphasized on allergen avoidance and exposure control as a  
192 fundamental treatment in all step of treatment. Environmental exposure of dust mite can be  
193 controlled by removal of facilitative factor for mite growth and survival, clean or remove mite  
194 reservoirs and get rid of the mites.<sup>6</sup>The most important facilitative factor for mite survival is  
195 relative humidity (RH) in the ambient environment.<sup>9</sup>Maintaining RH in the house to less than  
196 55% has been recommended to control dust mites and their allergen in homes in temperate  
197 climate<sup>10</sup> If there is a changing in temperature that results in increasing the RH only few  
198 hours can promote the growth of dust mites.<sup>6</sup>

199 The present study has demonstrated our newly invented temperature and humidity control  
200 machine was able to decrease the level of dust mite allergen in the bedroom of allergic  
201 rhinitis patients from Thailand, the high humidity country. Previous studies have shown the  
202 ineffectiveness of portable dehumidifiers in reduction the level of dust mite antigens.<sup>11</sup>  
203 <sup>12</sup>Since RH is temperature dependent. The advantage of this newlyl invented machine is the  
204 ability to maintain stable RH in conjunction with stable temperature by running incorporated  
205 with air-conditioning under the automatic control using microprocessor.<sup>7</sup> Previous study has  
206 been demonstrated that maintaining daily indoor relative humidity below 50% RH but  
207 allowing RH above 50% for more than 2 hours daily resulted in dust mite's population  
208 growth.<sup>13</sup> As a result, a portable dehumidifier in home use may not be able to control the  
209 dust mite population due to the inability to maintain stable temperature and RH throughout  
210 24 hours.

211 After installing this novel machine, there was a modest but significantly improvement in total  
212 nasal symptom score as early as 2 months.However, there was no correlation with the level

213 dust mite antigen. Previous studies have recommended decreasing the level of Der p 1 and  
214 Der f 1 to lower than 2 microgram per gram dust in order to lower the risk of dust mite  
215 sensitization<sup>14</sup>. Exposure to 10 microgram of Der p 1 and Der f 1 per gram dust has been  
216 suggested as an exposure threshold for the development of asthma symptoms in already  
217 sensitized children<sup>15</sup>. In the present study, the levels of Der p 1 and Der f 1 from the  
218 bedrooms of the participating patients before machine installation were varied from 0.2-4  
219 microgram per gram dust. Three out of seven subjects exposed to dust mite antigen lower  
220 than 2 microgram per gram dust. Consequently, the lower level of initial dust mite antigen  
221 may result in poorer correlation with the symptom improvements. In addition, forty percent  
222 of the participating patients had mild but persistent symptoms. The efficacy of the machine in  
223 reduction TTNS may be stronger if there were more severe patients enrolled. Since, the  
224 objective measurements such as rhinomanometry or nasal peak flow were not evaluated in  
225 the present study. The improvement in these objective measurements may be demonstrated  
226 early than the significant changes of clinical symptoms. There was a significant reduction of  
227 the level of dust mite antigen after machine installation. As a result, the significant  
228 improvement of clinical symptom may be demonstrated if the machine has been used for the  
229 longer duration.

230

231 The limitation of the present study is this novel machine is not commercially available and  
232 under developed. There are limited numbers of the machine which resulted in little number  
233 of enrolled patients. In addition due to the study period is 6 months, this may result in the  
234 difference in the season among patients. Nevertheless, this machine was demonstrated to  
235 be able to control the stable temperature and humidity,<sup>7</sup> the difference in the season should  
236 have minimal effect on the RH. There is no control patients in the present study, the placebo  
237 effect cannot be excluded for the improvement of the clinical symptoms. In addition, other  
238 methods that can control or decrease the level of dust mite were not monitor in the present

239 study. Further study on the efficacy of the machine in clinical practice needs more  
240 participating patients, longer duration of study and non-intervention group.

241 In conclusion, this pilot study has demonstrated that the newly invented temperature and  
242 humidity control machine was able to decrease the level of dust mite antigen in the bedroom  
243 of dust mite sensitized allergic rhinitis children. There was also a modest improvement in  
244 clinical symptoms of allergic rhinitis. Larger and well control studies are required to confirm  
245 the efficacy of this machine.

246

- 247 1. Bunnag, C., P. Jareoncharsri, P. Tantilipikorn, P. Vichyanond, and R. Pawankar, *Epidemiology*  
248 *and current status of allergic rhinitis and asthma in Thailand -- ARIA Asia-Pacific Workshop*  
249 *report*. Asian Pac J Allergy Immunol, 2009. 27: 79-86.
- 250 2. Brozek, J.L., J. Bousquet, C.E. Baena-Cagnani, S. Bonini, G.W. Canonica, T.B. Casale, et al.,  
251 *Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision*. J Allergy Clin  
252 Immunol, 2010. 126: 466-76.
- 253 3. Bousquet, J., J. Reid, C. van Weel, C. Baena Cagnani, G.W. Canonica, P. Demoly, et al.,  
254 *Allergic rhinitis management pocket reference 2008*. Allergy, 2008. 63: 990-6.
- 255 4. Andiappan, A.K., K.J. Puan, B. Lee, A. Nardin, M. Poidinger, J. Connolly, et al., *Allergic airway*  
256 *diseases in a tropical urban environment are driven by dominant mono-specific sensitization*  
257 *against house dust mites*. Allergy, 2014. 69: 501-9.
- 258 5. Sritipsukho, P., *Aeroallergen sensitivity among Thai children with allergic respiratory*  
259 *diseases: a hospital-based study*. Asian Pac J Allergy Immunol, 2004. 22: 91-5.
- 260 6. Portnoy, J., J.D. Miller, P.B. Williams, G.L. Chew, J.D. Miller, F. Zaitoun, et al., *Environmental*  
261 *assessment and exposure control of dust mites: a practice parameter*. Ann Allergy Asthma  
262 Immunol, 2013. 111: 465-507.
- 263 7. Sookahaiya T, M.V., Thepa S., *Assessment of the thermal environment effect a human*  
264 *comfort and health for the development of novel air conditioning system in tropical regions*.  
265 Energy Build, 2010. 42: 1692-1702.
- 266 8. Anantasit N., K.W., Direkwattanachai C., Manuyakorn W., Vilaiyuk S., Benjaponpitak S.,  
267 *Aeroallergen Sensitization Among Children with Respiratory*  
268 *Allergy in Ramathibodi Hospital, Bangkok*. J Allergy Clin Immunol, 2010. 125: AB17.
- 269 9. Arlian, L.G., *Water balance and humidity requirements of house dust mites*. Exp Appl Acarol,  
270 1992. 16: 15-35.
- 271 10. Arlian, L.G., J.S. Neal, M.S. Morgan, D.L. Vyszenski-Moher, C.M. Rapp, and A.K. Alexander,  
272 *Reducing relative humidity is a practical way to control dust mites and their allergens in*  
273 *homes in temperate climates*. J Allergy Clin Immunol, 2001. 107: 99-104.
- 274 11. Custovic, A., S.C. Taggart, J.H. Kennaugh, and A. Woodcock, *Portable dehumidifiers in the*  
275 *control of house dust mites and mite allergens*. Clin Exp Allergy, 1995. 25: 312-6.
- 276 12. Hyndman, S.J., L.M. Vickers, T. Htut, J.W. Maunder, A. Peock, and T.W. Higenbottam, *A*  
277 *randomized trial of dehumidification in the control of house dust mite*. Clin Exp Allergy, 2000.  
278 30: 1172-80.

279 13. Arlian, L.G., J.S. Neal, and D.L. Vyszynski-Moher, *Reducing relative humidity to control the*  
280 *house dust mite Dermatophagoides farinae*. J Allergy Clin Immunol, 1999. 104: 852-6.

281 14. Kuehr, J., T. Frischer, R. Meinert, R. Barth, J. Forster, S. Schraub, et al., *Mite allergen*  
282 *exposure is a risk for the incidence of specific sensitization*. J Allergy Clin Immunol, 1994. 94:  
283 44-52.

284 15. Custovic, A. and M. Chapman, *Risk levels for mite allergens. Are they meaningful?* Allergy,  
285 1998. 53: 71-6.

286

287